| Jason Ashcraft, RPH | |
|
10 W Main St, Austin, IN 47102-1304 | |
| (812) 794-4311 | |
| Not Available |
| Full Name | Jason Ashcraft |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 10 W Main St, Austin, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467895896 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 26018912A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jason Ashcraft, RPH 10 W Main St, Austin, IN 47102-1304 Ph: () - | Jason Ashcraft, RPH 10 W Main St, Austin, IN 47102-1304 Ph: (812) 794-4311 |
News Archive
Universal Detection Technology, a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, announced today that it has received its first purchase order from the Company's newly signed Israeli Distributor, M.D. Paled.
A new report from an ER physician group measured "access to care, quality and patient safety, liability, injury prevention and disaster preparedness," offering a snapshot of national and state policies affecting emergency medicine.
Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO's confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.
Sleep apnea is a common disease that affects millions of people all over the world, and if left undiagnosed and untreated can cause serious health complications. GE Sensing & Inspection Technologies has developed the Nova Pressure Amplified (NPA) series of pressure sensors for medical devices. Small and effective, the NPA is a critical component in creating cost-effective sleep apnea monitors that are more accurate and reliable than those currently on the market.
Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.
› Verified 9 days ago
Mr. Jeffrey Lynn Wells, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10 W Main St, Austin, IN 47102 Phone: 812-794-4311 Fax: 812-794-2514 |